STAT7h
Pharmalittle: We’re reading about FDA morale, pharma removing DEI goals, and more
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
FierceBiotech1d
Genentech archives diversity reports amid site update, examines ‘potential implications of executive orders’
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
Healio4h
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
FierceBiotech4d
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
Drugmaker Roche’s US Biotech Unit Pulls DEI Targets From Website
Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...
Hosted on MSN7d
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
BioSpace1d
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
FDA Approves New Tablet Form of Evrysdi for Treatment of Spinal Muscular Atrophy
About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...
Business Wire10d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced ...
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...